Q3 EPS Estimate for Armata Pharmaceuticals Lifted by Analyst

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Investment analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Armata Pharmaceuticals in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.42) per share for the quarter, up from their prior estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.46) EPS.

Armata Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:ARMP opened at $2.55 on Friday. The firm’s 50 day simple moving average is $2.22. Armata Pharmaceuticals has a twelve month low of $0.90 and a twelve month high of $2.96. The company has a market cap of $92.39 million, a P/E ratio of -2.48 and a beta of 0.99.

Institutional Trading of Armata Pharmaceuticals

A hedge fund recently bought a new stake in Armata Pharmaceuticals stock. GSB Wealth Management LLC bought a new position in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 30,000 shares of the company’s stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals at the end of the most recent reporting period. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.